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A B S T R A C T
The successful use of recombinant activated factor VII (rFVIIa), in treating massive, life-threatening haemoptysis in a
55-year-old male patient with chronic necrotising aspergillosis, is reported. Patient diagnosed with chronic necrotising
aspergillosis three months ago was admitted to our department with massive haemoptysis. Patient was treated as outpa-
tient with itraconazole. One day post-admission, two doses of rFVIIa (30 mg·kg–1) were administered and the haemo-
ptysis was successfully resolved. Two further doses of rFVIIa (30 mg·kg–1) were given the following day, and after that
there were no more recurrences of pulmonary haemorrhage. No thromboembolic or other adverse events were observed
following rFVIIa therapy. Our findings suggest that use of rFVIIa may represent a safe and effective treatment choice for
patients with haemoptysis due to aspergillosis.
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Introduction
Aspergillus is a ubiquitous soil-dwelling fungus that
can be transmitted to humans via inhalation of airborne
spores1 Chronic necrotising aspergillosis (CNA) describes
a destructive process of the lung caused by Aspergillus
spp. invasion, and is most prevalent among patients with
chronic lung disease or mild immunosuppression1.
The process is different from aspergilloma in that
there is local invasion of the lung tissue, not needed pre-
existing cavity, although the same can develop as a conse-
quence of fungi destruction. In contrast to invasive as-
pergillosis, in CNA there is no vascular invasion or
dissemination to other organs and the course of the dis-
ease is slowly over months to years.
Haemoptysis occurs in approximately 10% of patients
with CNA1, carrying a mortality rate of 2–14%2. Bleeding
usually occurs from bronchial blood vessels caused by lo-
cal invasion of blood vessels, and/or endotoxins released
by the fungus with hemolytic properties. In cases of mild
haemoptysis, medical therapy involves bed rest, humidi-
fied oxygen, administration of cough suppressants and
postural drainage. Surgical intervention can be consid-
ered in patients with massive haemoptysis, though the
surgical treatment of CNA remains hazardous and con-
troversial3. Therefore, alternative haemostatic treatment
strategies are clearly needed for CNA patients with hae-
moptysis who are unsuitable candidates for surgical in-
tervention.
We report the successful use of recombinant activated
factor VII (rFVIIa) to treat a case of massive, life-threat-
ening haemoptysis in a patient with CNA.
Case Report
We report a 55-year-old man with a history of tuber-
culosis 20 years ago and subsequent residual fibrothorax
and bilateral pleural adhesions. One year before his first
admission to our centre, he was diagnosed as sarcoidosis
with severe skin involvement which required continuous
treatment with varying doses of corticosteroid (pred-
nisolone). This treatment was discontinued 3 weeks be-
fore his first admission to our hospital with symptoms of
lung infection: productive cough, fever, night sweats and
progressive dyspnoea. The chest radiograph showed an
infiltrative process in upper lobes with adjacent pleural
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thickening. He received different antibiotic therapies but
failed to respond to treatment. Aspergillosis was con-
firmed following isolation of Aspergillus spp. in cultures
derived from the sputum and bronchoscopic samples.
The patient was treated with Aphothericin B intrave-
nously followed with prolonged oral itraconazole therapy
on an outpatient basis.
Two months later, the patient was re-admitted to the
hospital with coughing and massive, life-threatening
haemoptysis, approximately 500 mL of blood during the
first day. He was normotensive and tachycardic, with a
normal full blood count and coagulation parameters (Ta-
ble 1). A CT scan revealed bilateral retracted dysfunc-
tional upper lobes and a thick, irregular-walled cavity in
the right upper lobe (with no coincidental aspergilloma),
chronic active inflammation and alveolar haemorrhage
(Figure 1).
The patient was treated with oxygen, antitussive
drugs and sedatives, but with poor response. Bronchos-
copy revealed a great amount of fresh blood in the tra-
chea and both main bronchi, but surgical resection or
other invasive procedures were not possible owing to
scarring, pleural adhesions, diffuse bilateral disease and
high risk of further bleeding and spreading of infection.
On the day after admission, the patient therefore re-
ceived two bolus doses of rFVIIa (30 mg·kg–1) 2 hours
apart, with immediate resolution of haemoptysis. Re-
bleeding occurred the next day, so two further doses of
rFVIIa were given, with similarly successful results. No
thromboembolic or other adverse events occurred, and
no further pulmonary haemorrhage was observed. The
patient’s coagulation status before and after treatment
with rFVIIa is shown in Table 1.
Following treatment with rFVIIa, computed tomogra-
phy revealed the presence of chronic bronchopulmonary
lesions associated with CNA, with no evident disease dy-
namics (Figure 2). The patient was discharged on the
14th day post-admission following successful resolution of
symptoms and satisfactory radiographic findings. Pa-
teint was later followed for one year without recurrent
bleeding.
Discussion
Recombinant FVIIa is licensed for the treatment of
bleeding in patients with haemophilia A or B and inhibi-
tors. It has recently been approved in Europe for the
treatment of haemorrhage in FVII deficiency and Glanz-
mann’s thrombasthenia, and increasing evidence sug-
gests that rFVIIa may have an additional haemostatic
role in previously non –coagulopathic patients in a vari-
ety of bleeding situations4–6. The agent has also shown ef-
ficacy in treating pulmonary haemorrhage of various
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TABLE 1
COAGULATION STATUS BEFORE AND AFTER RECOMBINANT ACTIVATED FACTOR VII (rFVIIa) ADMINISTRATION
Admission Treatment with rFVIIa
Parameter Day 1 Day 2 Day 3 Day 7 Day 14
Haemoglobin (g·L–1)* 125 115 106 104 94
Platelets (´109·L–1) 229 220 212 345 293
PT (%)† 75 99 99 100 82
INR‡ 1.27 1.0 1.0 1.0 1.2
APTT (s)§ 25.1 26.4 24.5 26.0 28.1
Fibrinogen (g·L–1)|| 5.1 5.4 5.5 4.4 5.00
D-dimers (mg·L–1) ¶ – 0.25 – – 0.36
Factor VIII** – – – – 2.53
PT – prothrombin time; INR – international normalized ratio; APTT – activated partial thromboplastin time.
*Normal range 140–180 g·L–1, †Normal range 70–140%, ‡Therapeutic range 2–4, §Normal range 24–35s, ||Normal range 1.7–3.9 g·L–1,
¶Normal range <0.25 mg·L–1, **Normal range 0.6–1.8.
Fig. 1. Chest radiograph: bilateral retracted dysfunctional upper
lobes with thick, irregular-walled cavity on right upper lobe.
aetiologies7–12 when given in doses of 90 mg·kg–1; this is in
line with the dose recommended for the treatment of
bleeding in haemophilia patients (90–120 mg·kg–1). In
contrast, we achieved successful haemostasis in our pa-
tient using four bolus doses of 30 mg·kg–1over a two day
period. This case showed that in patients with acute lung
bleeding due to chronic necrotising aspergillosis could be
successfully stopped with Recombinant FVIIa, even in a
dose smaller than recommended for haemophilia.
Surgery was not considered to be a feasible option for
our patient due to the presence of bilateral lesions, pleu-
ral adhesions and chronic changes in the lower parts of
the lungs. Bronchial artery embolisation should be con-
sidered as a temporary procedure in these patients, al-
though it rarely results in control of haemoptysis be-
cause of the massive collateral vessels and high incidence
of recurrent bleeding. Furthermore, we were unable to
perform bronchial artery embolisation as both main
bronchial passageways were filled with blood and the ex-
act location of the massive bleeding could not be deter-
mined. Following unsuccessful use of conventional thera-
pies, the decision was made to administer two doses of
rFVIIa (30 mg·kg–1). Haemoptysis was immediately re-
solved, and rebleeding the following day was also treated
successfully with two further bolus doses.
No thromboembolic or other adverse events were ob-
served in our patient. To date, rFVIIa has demonstrated
a highly favourable efficacy and safety profile across a va-
riety of indications and a wide range of doses13–15, an ob-
servation that may be explained by the agent’s mode of
action. Recent theories suggest that rFVIIa may act by
binding weakly to activated platelets and thus improving
thrombin formation independently of tissue factor16.
Such localisation of rFVIIa activity explains its haemo-
static efficacy and ensures that systemic activation of co-
agulation – and subsequent risk of thrombotic events – is
reduced16.
Only few randomised trials proved efficacy and safety
of recombinant FVIIa17,18, none of them in acute lung
bleeding.
Nonetheless, we suggest that rFVIIa may play an im-
portant role as »universal« haemostatic agent in manag-
ing severe, life-threatening haemoptysis in non-coagulo-
pathic patients with pulmonary aspergillosis, particularly
when surgical intervention is contraindicated. Further
information on clinical application of this agent is needed.
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Fig. 2. Computed tomographic scan revealing pleural thickening
of bilateral upper lobes.
AKTIVIRANI REKOMBINANTNI ^IMBENIK VII U BOLESNIKA S MASIVNIM
HEMOPTIZAMA KAO POSLJEDICOM KRONI^NE NEKROTIZIRAJU]E ASPERGILOZE
S A @ E T A K
U radu je prikazana uspje{na uporaba aktiviranog rekombinantnog ~imbenika VIIa (rfVIIa), u lije~enju 55-godi{njeg
bolesnika, sa masivnim, po `ivot ugro`avaju}im hemoptizama kao posljedicom kroni~ne nekrotiziraju}e aspergiloze.
Bolesnik, kojem je tri mjeseca pred prijem postavljena dijagnoza kroni~ne nekrotiziraju}e aspergiloze, primljen je pu-
tem hitne slu`be zbog masivnih hemoptiza. Ambulantno je do tada lije~en itrakonazolom. Dan nakon prijema, bolesnik
je dobio dvije doze rfVIIa (30 mg·kg–1) nakon ~ega je do{lo do zaustavljanja krvarenja. Dvije dodatne doze rfVIIa (30
mg·kg–1) bolesnik je dobio slijede}i dan, te potom vi{e nije bilo znakova krvarenja. Nije primije}eno tromboembolijskih
incidenata, niti ostalih nuspojava. Ovaj slu~aj ukazuje da je primjena rfVIIa u bolesnika s krvarenjem iz plu}a zbog
kroni~ne nekrotiziraju}e aspergiloze sigurna i u~inkovita, te predstavlja dodatnu terapijsku opciju u bolesnika sa ma-
sivnim hemoptizama u bolesnika sa apergilozom plu}a.
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